<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>Evidence | LiquidMammo™</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description" content="Clinical evidence and validation plan for LiquidMammo™, a microRNA-based liquid biopsy designed to complement mammography—especially in dense breasts." />

  <!-- Stylesheet -->
  <link rel="stylesheet" href="assets/css/styles.css" />

  <!-- Favicon -->
  <link rel="icon" href="favicon.png" type="image/png" />
</head>

<body>

<header class="container">
  <nav>
    <a href="index.html">← Home</a>
  </nav>
</header>

<main class="container">

  <h1>Clinical Evidence & Validation</h1>

  <section class="section-tight">
    <p>
      Our validation program includes analytical and clinical studies aligned with CLIA Laboratory Developed Test (LDT) practices.
      As data lock occurs, we will publish sensitivity/specificity, PPV/NPV, calibration, and density‑stratified performance.
      LiquidMammo is not yet FDA‑cleared or FDA‑approved.
    </p>
  </section>

  <section class="section-tight">
    <h2>Why complementary screening is needed</h2>
    <ul class="list-tight">
      <li>False‑negatives in screening mammography are real (≈1 in 8 overall).</li>
      <li>False‑negative rates have risen across large U.S. datasets in the last decade.</li>
      <li>Detection yield per 1,000 screens is modest; interval cancers are higher in dense breasts.</li>
      <li>False‑positives accumulate (≥1 over 10 years for ~50–60% of screened women).</li>
    </ul>
  </section>

  <section class="panel-light section-tight">
    <h2>The challenge in younger women</h2>
    <p>Mammography limitations are amplified in younger women due to higher breast density:</p>
    <ul class="list-tight">
      <li><strong>Dense breasts are common under 50.</strong> Roughly 50–74% of women aged 40–49 have heterogeneously or extremely dense breasts (BI‑RADS C or D), compared with 20–36% of women in their 70s.</li>
      <li><strong>Sensitivity drops with density.</strong> Mammography sensitivity can fall from ≈86% in fatty breasts to ≈61% in extremely dense breasts. In women under 40, first‑screening sensitivity is ≈77%.</li>
      <li><strong>Cancers are masked.</strong> Among women younger than 56, many interval cancers (diagnosed within 12 months of a negative screen) are attributable to dense tissue masking.</li>
      <li><strong>Lower detection yield in younger cohorts.</strong> Cancer detection per 1,000 screens is ~1.7 in women under 40 and ~2.3 at ages 40–44, versus ~5.1 overall.</li>
      <li><strong>Higher false‑positive burden starting at age 40.</strong> Cumulative probability of ≥1 false‑positive over 10 years is ~50–60%.</li>
    </ul>
    <p class="small">
      These statistics underscore why a complementary, non‑invasive, biology‑based signal may be especially valuable for younger, dense‑breasted populations.
    </p>
  </section>

  <section class="section">
    <h2>References (public)</h2>
    <ul class="list-tight">

      <li>
        <a href="https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection" target="_blank" rel="noopener">
          American Cancer Society – <em>Limitations of Mammograms</em> (false‑negatives, false‑positives)
        </a>
      </li>

      <li>
        <a href="https://www.komen.org/breast-cancer/screening/mammography/mammography-accuracy/" target="_blank" rel="noopener">
          Susan G. Komen – <em>Accuracy of Mammograms</em> (sensitivity, false‑positive burden)
        </a>
      </li>

      <li>
        <a href="https://www.radiologybusiness.com/topics/clinical/radiology/ajr-false-negative-mammography-rates-rise" target="_blank" rel="noopener">
          Radiology Business (AJR) – <em>U.S. false‑negative trends</em>
        </a>
      </li>

      <li>
        <a href="https://densebreast-info.org/screening-technologies/screening-performance-and-cancer-detection-rates/" target="_blank" rel="noopener">
          DenseBreast‑info – <em>Cancer detection per 1,000 screens</em>
        </a>
      </li>

      <li>
        <a href="https://pubs.rsna.org/doi/full/10.1148/rg.2018170108" target="_blank" rel="noopener">
          RSNA RadioGraphics – <em>Dense breast challenges and supplemental screening</em>
        </a>
      </li>

      <li>
        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5375631/" target="_blank" rel="noopener">
          BCSC – <em>Screening performance benchmarks</em> (PMC 5375631)
        </a>
      </li>

      <li>
        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200066/" target="_blank" rel="noopener">
          Sprague et al. – <em>Prevalence of dense breasts in the U.S.</em> (PMC 4200066)
        </a>
      </li>

      <li>
        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902813/" target="_blank" rel="noopener">
          Yankaskas et al. – <em>Performance of first mammography in women younger than 40</em> (PMC 2902813)
        </a>
      </li>

      <li>
        <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa062434" target="_blank" rel="noopener">
          Boyd et al. (NEJM 2007) – <em>Mammographic density and detection</em>
        </a>
      </li>

      <li>
        <a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening" target="_blank" rel="noopener">
          USPSTF (2024) – <em>Breast cancer screening recommendations</em>
        </a>
      </li>

      <li>
        <a href="https://www.cdc.gov/cancer/dcpc/research/articles/dense-breasts.htm" target="_blank" rel="noopener">
          CDC – <em>About Dense Breasts</em>
        </a>
      </li>

    </ul>
  </section>

</main>

<footer>
  <div class="container footer-grid">
    <div>
      <strong>LiquidMammo™</strong><br/>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC and operates out of
        LabCentral in Cambridge, MA (MIT innovation ecosystem).
      </p>
    </div>
    <div class="footer-logo" style="justify-content:flex-end;text-align:right">
      <img src="assets/logos/multiomics-logo.png" alt="MultiOmics Inc. logo (subtle)" />
      <div class="footer-note" style="line-height:1.2">
        Developed by<br/>MultiOmics Inc.
      </div>
    </div>
  </div>
  <div class="container footer-note">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    <a href="privacy.html">Privacy & Compliance</a> •
    <a href="contact.html">Order / Kits</a>
  </div>
</footer>

</body>
</html>


